According to a new guidelines recommended by American Academy of Family Physicians metformin is the first-choice treatment for obese patients with type 2 diabetes in compare with the other diabetic Drugs. The American College of Physicians approved the updated clinical practice guidelines because of new research into diabetes drugs. As per the study conducted by ACP President Dr. Nitin Damle Metformin is a cheaper medicine compare with Invokana or the other medicine use to treat diabetes and it is associated with fewer adverse effects. The Food and drugs administration approved the new drug stating that is an effective treatment for diabetes with fewer risk. A study on Metformin suggest that it has very rare side effect less than 1 person per 100,000 patients taking metformin found with lactic acidosis in the body. Lactic acidosis is very dangerous and rare found in the patients who have renal dysfunction, liver disease, and heavy alcohol ingestion.
Metformin is also called a euglycemic is the most frequently prescribed medication for type 2 diabetes worldwide. In 2012 it was approved by U.S Food and Drugs Administration. The drug works by making the kidneys remove sugar from the body through the urine rather than have it be reabsorbed into the blood. Metformin helps to prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. The medication is uses with diet and exercise to lower blood sugar in adults with type 2 diabetes. Metformin does not cause weight gain, and is usually the first choice of medication to treat type 2 diabetes. According to studies conducted on patient who took Invokana instead of Metformin suffered with several side effects such as ketoacidosis, kidney failure and other harmful effects associated with the medicine.
More than 100,000 people are affected with Kidney failure in the United States each year due to Invokana medication. The U.S. Food and Drug Administration (FDA) has announced the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines including J&J’s Invokana/Invokamet (Canagliflozin) and Farxiga/Xigduo XR in June this year. The FDA suggested patients not to stop or change their diabetes medicines without first talking to their health care professional. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, are facing thousands of Invokana lawsuits due to serious injury caused by Invokana. The plaintiff’s claims that manufacturers failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious and life threatening medical complications associated with these drug.
People taking canagliflozin are urged to monitor their health closely and discuss with their doctor about the benefits and risks of the drug. If you or someone you love who was prescribed Invokana and then suffered from ketoacidosis, kidney failure, Heart Attack or Stroke may be eligible to file a personal injury lawsuit against the drug’s manufacturer. The Drugsclaim Lawyers and Attorneys are investigating claims that Invokana may be linked to kidney failure, cardiovascular complications and bone fractures. In filing personal injury lawsuits, injured patients seek compensation for medical expenses, lost work and pain and suffering, among other damages.